Roles of Fusobacterium nucleatum in the Progression of Respiratory Diseases.

Journal of Microbes and Infections ›› 2025, Vol. 20 ›› Issue (2) : 120-128.

Welcome to visit Journal of Microbes and Infections,
Journal of Microbes and Infections ›› 2025, Vol. 20 ›› Issue (2) : 120-128.

Roles of Fusobacterium nucleatum in the Progression of Respiratory Diseases.

Author information +
History +

Abstract

The interaction between microorganisms and the human host is complex. Fusobacterium nucleatum, a commensal bacterium in the human body, can lead to chronic inflammatory responses under pathological conditions, playing an important role in plaque formation and bacterial pathogenicity through its various adhesion proteins. In recent years, increasing evidence has shown a link between periodontitis and respiratory diseases, with common periodontal pathogens detected in samples from various respiratory diseases. These pathogens can promote the adhesion and invasion of respiratory pathogens, enhance inflammatory responses and apoptosis in respiratory epithelial cells, induce mucin overexpression, and disrupt the balance of the respiratory immune system, thereby influencing the occurrence and development of respiratory diseases. In this review, we examine the association between Fusobacterium nucleatum and respiratory diseases (mainly chronic obstructive pulmonary disease, lung infectious diseases, lung cancer, and bronchitis) and summarize the mechanisms and molecular changes by which Fusobacterium nucleatum promotes the progression of related diseases. This provides new insights into the pathogenesis of respiratory diseases and offers new ideas for developing treatment and prevention strategies for these conditions.

Key words

Fusobacterium nucleatum / Chronic obstructive pulmonary disease (COPD) / Pneumonia / lung cancer

Cite this article

Download Citations
Roles of Fusobacterium nucleatum in the Progression of Respiratory Diseases.[J]. Journal of Microbes and Infections. 2025, 20(2): 120-128

References

[1] Noiri Y, Li L, Ebisu S. The localization of periodontal diseaseassociated bacteria in human periodontal pockets[J]. J Dental Res, 2001, 80(10): 1930-1934.
[2] Kamila S, Kamil W,?Karolina J. Fusobacterium nucleatum-Friend or foe?[J]. J Inorg Biochem,?2021, 224:111586.
[3] Chen YX, Huang ZJ, Tang ZM, et al. More than just a periodontal pathogen -the research progress on Fusobacterium nucleatum[J]. Front cell infect microbiol. 2022, 3:12:815318.
[4] 王菡侨, 刘树卿, 杨敬芳, 等. 192 例肺部厌氧菌感染的菌谱分析[J]. 中华医院感染学杂志, 2001, 11(1):68-69.
[5] 谭丽思, 王宏岩, 赵海礁, 等。呼吸道内具核梭杆菌与阻塞性肺疾病相关性研究[J]. 中国实用口腔科杂志, 2013,6(11):664-667.
[6] Vandekerckhove B,van Steenberghe D. The role of periodontal diseases in bad breath [J]. Ned Tijdschr Tandheelkd, 2002, 109(11):430-433.
[7] Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease [J]. N Engl J Med. 2019, 381(13):1257-66.
[8] Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease[J]. Lancet. 2012,379(9823):1341-51.
[9] Terada K, Muro S, Ohara T, et al. Abnormal swallowing re?ex and COPD exacerbations[J]. Chest. 2010, 137(2):326-32.
[10] Lee SW, Kuan CS, Wu LS, et al. Metagenome and metatranscriptome pro?ling of moderate and severe COPD sputum in Taiwanese Han Males [J]. PLoS One. 2016, 11(7):e0159066.
[11] Zhou X, Han J, Liu Z, et al. Effects of periodontal treatment on lung function and exacerbation frequency in patients with chronic obstructive pulmonary disease and chronic periodontitis: a 2-year pilot randomized controlled trial [J]. J Clin Periodontol. 2014,41(6):564-72.
[12] Li J, Ye Z. The potential role and regulatory mechanisms of MUC5AC in chronic obstructive pulmonary disease [J]. Molecules. 2020, 25(19):4437.
[13] Caramori G, Adcock IM, Di Stefano A, et al. Cytokine inhibition in the treatment of COPD [J]. Int J Chron Obstruct Pulmon Dis. 2014, 9:397-412.
[14] Ilumets H, Rytila PH, Sovijarvi AR, et al. Transient elevation of neutrophil proteinases in induced sputum during COPD exacerbation [J]. Scand J Clin Lab Invest. 2008, 68(7):618-23.
[15] Ryuta S,?Noriaki K,?Tadayoshi K,?et al. Fusobacterium nucleatum exacerbates chronic obstructive pulmonary disease in elastase-induced emphysematous mice[J]. FEBS Open Bio.?2022, 12(3):638-648.
[16] Ryuta Suzuki, Noriaki Kamio, Kozue Sugimoto, et al. Periodontopathic Bacterium Fusobacterium nucleatum Affects Matrix Metalloproteinase-9 Expression in Human Alveolar Epithelial Cells and Mouse Lung[J]. In Vivo. 2022, 36(2):649-656.
[17] Li Q, Wang HY, Tan LS, et al. Oral pathogen Fusobacterium nucleatum coaggregates with Pseudomonas aeruginosa to modulate the inflammatory cytotoxicity of pulmonary epithelial cells[J]. Front Cell Infect Microbiol. 2021, 19;11:643913.
[18] Li Q,?Tan LS,?Wang HY,?et al. Fusobacterium nucleatum?interaction with?Pseudomonas aeruginosa?induces biofilm-associated antibiotic tolerance via?Fusobacterium?adhesin A[J]. ACS Infect Dis.?2020, 6(7):1686-1696.
[19] Saygun I, Nizam N, Keskiner I, et al. Salivary infectious agents and periodontal disease status[J]. J Periodontal Res. 2011, 46(2):235-9.
[20] Boyanova L, Vladimir D, Gergova G, et al. Anaerobic microbiology in 198 cases of pleural empyema: a Bulgarian study[J]. Anaerobe. 2004, 10(5):261-7.
[21] Dyrhovden R,?Eagan TM,?Fl?tten ?,?et al. Pleural empyema caused by Streptococcus intermedius and Fusobacterium nucleatum - a distinct entity of pleural infections[J]. Clin Infect Dis.?2023, 77(10):1361-1371.
[22] Nagaoka K, Yanagihara K, Harada Y, et al. Quantitative detection of periodontopathic bacteria in lower respiratory tract specimens by real-time PCR[J]. J Infect Chemother. 2017, 23(2), 69-73.
[23] De Carvalho Baptista IM, Martinho FC, Nascimento GG, et al. Colonization of oropharynx and lower respiratory tract in critical patients: Risk of ventilator-associated pneumonia[J]. Arch Oral Biol. 2018, 85, 64–69.
[24] Sun?Y, Dong?H,?Zhang?N,?et al. Empyema caused by?Fusobacterium nucleatum?with squamous cell carcinoma of the lung: a case report and literature review[J]. Front Med (Lausanne).?2023, 25;10:1099040. ?
[25] Claudio Hoffmeister B,?Karen Ducasse C,?Marcela González L,?et al. Pulmonary and thoracic infection by Fusobacterium nucleatum[J]. Andes Pediatr.?2021, 92(1):93-98.
[26] Masters IB, Isles AF, Grimwood K. Necrotizing pneumonia: an emerging problem in children?[J] Pneumonia (Nathan).?2017, 25:9:11.
[27] Fukushima EA,?Bhargava A. Unusual case of necrotizing pneumonia caused by Fusobacterium nucleatum complicating influenza a virus infection[J]. Anaerobe.?2021, 69:102342.
[28] Bao L, Zhang C, Lyu J, et al. Beware of pharyngeal Fusobacterium nucleatum in COVID-19[J]. BMC Microbiol. 2021, 21(1):277.
[29] Wolff L, Martiny D, Deyi VYM, et al. COVID-19-Associated Fusobacterium nucleatum Bacteremia, Belgium[J]. Emerg Infect Dis. 2021, 27(3), 975–977.
[30] Takahashi Y,?Watanabe N,?Kamio N, et al.?Expression of the SARS-CoV-2 receptor ACE2 and proinflammatory cytokines induced by the periodontopathic bacterium?Fusobacterium nucleatum?in human respiratory epithelial cells[J]. Int J Mol Sci.?2021, 22(3):1352.
[31] Dessì A, Bosco A, Pintus R, et al. Fusobacterium nucleatum and alteration of the oral microbiome: From pregnancy to SARS-CoV-2 infection[J]. Eur Rev Med Pharmacol Sci. 2021, 25(13), 4579-4596.
[32] Itzhak Brook, Edith H Frazier. Immune response to Fusobacterium nucleatum and Prevotella intermedia in the sputum of patients with acute exacerbation of chronic bronchitis[J]. Chest. 2003,124(3):832-3.
[33] Chen ZG, Hui PC, Hui M, et al. Impact of preservation method and 16S rRNA hypervariable region on gut microbiota profiling[J]. mSystems.2019,26;4(1):e00271-18.
[34] Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2[J]. Nat Biotechnol. 2019, 37(8):852-857.
[35] Jack A Gilbert, Janet K Jansson, Rob Knight. The earth microbiome project: successes and aspirations[J]. BMC Biol.2014, 22:12:69.
[36] Geng FX, Zhang YJ, Lu Z. Fusobacterum nucleatum caused DNA damage and promoted cell proliferation by the Ku70/p53 pathway in oral cancer cells[J]. DNA Cell Biol. 2020, 39(1):144-151.
[37] Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin[J]. Cell Host Microbe. 2013, 14(2):195-206.
[38] Mai X, Genco RJ, LaMonte MJ, et al. Periodontal pathogens and risk of incident cancer in postmenopausal females: the buffalo osteoperio study[J]. J Periodontol. 2016, 87(3), 257-267.
[39] Chu S, Cheng Z, Yin Z, et al. Airway Fusobacterium is associated with poor response to immunotherapy in lung cancer[J]. OncoTargets Ther. 2022, 15, 201-213.
[40] Jiang XT,?Zhang Y,?Wang HY,?et al. In-depth metaproteomics analysis of oral microbiome for lung cancer[J].
Research (Wash D C).?2022,13:2022:9781578. ?
[41]Kentaro Nagaoka,?Katsunori Yanagihara,?Yoshitomo Morinaga,?et al. Detection of Fusobacterium nucleatum in two cases of empyema and lung abscess using paromomycin-vancomycin supplemented Brucella HK agar[J]. Anaerobe.?2017,43:99-101.
[42] Park K, Hur KH,?Sung H,?et al. Culture-negative Fusobacterium nucleatum brain abscess and pleural empyema cases revealed by 16S rRNA sequencing[J]. Clin Lab.?2023,69(4).

Accesses

Citation

Detail

Sections
Recommended

/